Organon & Co
OGNHealthcare·Drug Manufacturers - General·USA·Mid·NYSE·Nov 11 • 1:17 PM ET
13.86-0.03 (-0.18%)
2026-11-11 19:17 CET
Market cap
3,647.82 USD m
Revenue, TTM
6,099.00 USD m
Net income, TTM
213.00 USD m
Free cash flow, TTM
675.00 USD m
EPS diluted, TTM
0.77
P/E
18.03
Price
OGN against its 20, 50 and 200-day averages2050200miss
0.2% under the 52-week high of 13.89 on 10 Nov 2026. 52-week low 5.69 on 30 Mar 2026. Last 15 sessions, 1.1% high to low
Profile
OGN52-week range, 100% of the way up
5.6913.89
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
| Index | RUI |
|---|---|
| Employees | 10000 |
| IPO | May 14, 2021 |
| Beta | 1.49 |
| ATR, 14d | 0.05 |
| Rel volume | 0.42 |
| Short float | 7.55% |
| Insider own | 0.64% |
| Inst own | 80.96% |
Snapshot
6 groupsValuation
| Index | RUI |
|---|---|
| Market Cap | 3.64B |
| Enterprise Value | 10.74B |
| Income | 213.00M |
| Sales | 6.10B |
| Book/sh | 4.54 |
| Cash/sh | 5.54 |
| Dividend Est. | 0.08 (0.58%) |
| Dividend TTM | 0.08 (0.58%) |
| Dividend Ex-Date | Nov 09, 2026 |
| Dividend Gr. 3/5Y | -32.79% - |
| Payout | 47.41% |
| Employees | 10000 |
| IPO | May 14, 2021 |
Ratios
| P/E | 18.03 |
|---|---|
| Forward P/E | 3.82 |
| PEG | 1.24 |
| P/S | 0.60 |
| P/B | 3.05 |
| P/C | 2.50 |
| P/FCF | 5.39 |
| EV/EBITDA | 7.01 |
| EV/Sales | 1.76 |
| Quick Ratio | 1.51 |
| Current Ratio | 2.02 |
| Debt/Eq | 7.17 |
| LT Debt/Eq | 7.11 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | 0.77 |
|---|---|
| EPS next Y | 3.63 |
| EPS next Q | 0.88 |
| EPS this Y | -8.47% |
| EPS next Y | 8.36% |
| EPS next 5Y | 3.09% |
| EPS past 3/5Y | -41.56% -39.04% |
| Sales past 3/5Y | 0.23% -1.00% |
| EPS Y/Y TTM | -58.19% |
| Sales Y/Y TTM | -3.21% |
| EPS Q/Q | -1.91% |
| Sales Q/Q | -1.75% |
| Earnings | Aug 11 |
| EPS/Sales Surpr. | -6.59% 0.00% |
Ownership
| Insider Own | 0.64% |
|---|---|
| Insider Trans | -0.87% |
| Inst Own | 80.96% |
| Inst Trans | -3.28% |
| ROA | 1.58% |
| ROE | 20.30% |
| ROIC | 2.20% |
| Gross Margin | 53.53% |
| Oper. Margin | 19.61% |
| Profit Margin | 3.49% |
| SMA20 | 0.48% |
| SMA50 | 0.83% |
| SMA200 | 18.50% |
| Trades | - |
Technical
| Shs Outstand | 262.62M |
|---|---|
| Shs Float | 260.94M |
| Short Float | 7.55% |
| Short Ratio | 7.35 |
| Short Interest | 19.69M |
| 52W High | 13.89 -0.18% |
| 52W Low | 5.69 143.67% |
| Volatility | 0.48% 0.31% |
| ATR (14) | 0.05 |
| RSI (14) | 60.26 |
| Beta | 1.49 |
| Rel Volume | 0.42 |
| Avg Volume | 2.68M |
| Volume | 681,445 |
Performance
| Perf Week | 0.25% |
|---|---|
| Perf Month | 0.69% |
| Perf Quarter | 1.06% |
| Perf Half Y | 3.94% |
| Perf YTD | 93.38% |
| Perf Year | 84.38% |
| Perf 3Y | 24.69% |
| Perf 5Y | -60.07% |
| Perf 10Y | - |
| Recom | 3.00 |
| Target Price | 14.00 |
| Prev Close | 13.89 |
| Price | 13.86 |
| Change % | -0.18% |
Analyst ratings
latest 10 of 19| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Apr 28, 2026 | Upgrade | PPiper Sandler | Underweight → Neutral | $14 | +1.0% |
| Dec 09, 2025 | Initiated | BBarclays | Underweight | $7.50 | -45.9% |
| Oct 27, 2025 | Downgrade | PPiper Sandler | Overweight → Underweight | $5 | -63.9% |
| May 02, 2025 | Downgrade | EEvercore ISI | Outperform → In-line | ||
| Sep 06, 2024 | Downgrade | JJP Morgan | Neutral → Underweight | $18 → $20 | +44.2% |
| Nov 03, 2023 | Downgrade | GGoldman | Buy → Neutral | $33 → $16 | +15.4% |
| Sep 21, 2023 | Initiated | BBarclays | Overweight | $28 | +101.9% |
| Mar 16, 2023 | Initiated | RRaymond James | Outperform | $33 | +138.0% |
| Oct 14, 2022 | Downgrade | BBofA Securities | Neutral → Underperform | $27 → $25 | +80.3% |
| Sep 06, 2022 | Upgrade | PPiper Sandler | Neutral → Overweight | $37 → $34 | +145.2% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| VTRS | Viatris Inc | 24.00B |
| BHC | Bausch Health Companies Inc | 3.15B |
| AMRX | Amneal Pharmaceuticals Inc | 7.62B |
| PRGO | Perrigo Company plc | 2.32B |
| TEVA | Teva- Pharmaceutical Industries Ltd | 50.01B |
| PFE | Pfizer Inc | 166.61B |
| ANIP | ANI Pharmaceuticals Inc | 1.64B |
| ARQT | Arcutis Biotherapeutics Inc | 3.57B |
| PBH | Prestige Consumer Healthcare Inc | 2.08B |
| COLL | Collegium Pharmaceutical Inc | 764.77M |
Insider trading
latest 14 of 30| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Head of Mfg & Supply | Nov 07 '26 | Option Exercise | 0.00 | 3,626 | 0 | 22,101 | Nov 10 04:07 PM |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | Nov 07 '26 | Option Exercise | 0.00 | 6,447 | 0 | 43,879 | Nov 10 04:06 PM |
| Holzbaur Lynette | SVP and Corporate Controller | Nov 07 '26 | Option Exercise | 0.00 | 2,418 | 0 | 4,590 | Nov 10 04:05 PM |
| Holzbaur Lynette | SVP and Corporate Controller | Nov 05 '26 | Option Exercise | 0.00 | 3,038 | 0 | 3,038 | Nov 10 04:05 PM |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | Aug 11 '26 | Option Exercise | 0.00 | 11,519 | 0 | 41,566 | Aug 12 01:01 PM |
| JULIANA P DRINANE | Officer | Aug 05 '26 | Proposed Sale | 13.57 | 14,761 | 200,307 | Aug 05 04:26 PM | |
| Drinane Juliana Papa | Head of Mfg & Supply | Aug 05 '26 | Sale | 13.57 | 14,761 | 200,307 | 18,475 | Aug 05 04:04 PM |
| Holzbaur Lynette | Affiliate | May 06 '26 | Proposed Sale | 13.35 | 26,448 | 353,080 | May 08 08:31 PM | |
| Holzbaur Lynette | SVP and Corporate Controller | May 06 '26 | Buy | 13.35 | 26,448 | 353,080 | 52,851 | May 07 10:02 AM |
| Drinane Juliana Papa | Interim Head of Mfg & Supply | Mar 31 '26 | Option Exercise | 0.00 | 16,451 | 0 | 36,687 | Apr 02 04:26 PM |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | Mar 31 '26 | Option Exercise | 0.00 | 13,431 | 0 | 34,867 | Apr 02 04:18 PM |
| Karp Daniel | Executive VP, Corp. Dev. | Mar 31 '26 | Option Exercise | 0.00 | 18,053 | 0 | 71,653 | Apr 02 04:17 PM |
| Stahler Rachel A | Chief Information Officer | Mar 31 '26 | Option Exercise | 0.00 | 18,867 | 0 | 120,322 | Apr 02 04:14 PM |
| WALSH MATTHEW M | Chief Financial Officer | Mar 31 '26 | Option Exercise | 0.00 | 33,593 | 0 | 220,126 | Apr 02 04:13 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IJR | iShares Core S&P Small-Cap ETF | AUM: 106.27B |
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 79.59B |
| VBR | Vanguard Morningstar Small-Cap Value ETF | AUM: 37.76B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| SPSM | State Street SPDR Portfolio S&P 600TM Small Cap ETF | AUM: 16.06B |
| IJS | iShares S&P Small-Cap 600 Value ETF | AUM: 7.74B |
| SLYV | State Street SPDR S&P 600 TM Small Cap Value ETF | AUM: 5.01B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.25B |
| IWR | iShares Russell Mid-Cap ETF | AUM: 58.68B |
News
latest 14 of 200- New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System (Business Wire)
- Organon to Present New Analysis on VTAMA (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting (Business Wire)
- Organon: Q3 Earnings Snapshot (Associated Press)
- Organon Announces Quarterly Dividend (Business Wire)
- Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing (Business Wire)
- Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting (Business Wire)
- Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference (Business Wire)
- Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device (Business Wire)
- Organon Opens REMS Program for MIUDELLA Ahead of Anticipated Commercial Availability (Business Wire)
- Organon: Q2 Earnings Snapshot (Associated Press)
- Organon Announces Quarterly Dividend (Business Wire)
- New Analysis of Phase 3 Pooled Data for Organons VTAMA (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 (Business Wire)
- Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing (Business Wire)
- Organon to Present New Analysis on VTAMA (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting (Business Wire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-08-11 | 0.850 | 0.910 | 0.399 | 1,602 | 1,602 | 1 |
| 2026Q1 | 2026-04-30 | 0.710 | 0.829 | 0.555 | 1,460 | 1,488 | 7 |
| 2025Q4 | 2026-02-12 | 0.630 | 0.727 | -0.788 | 1,507 | 1,535 | 7 |
| 2025Q3 | 2025-11-10 | 1.010 | 0.936 | 0.614 | 1,602 | 1,574 | 6 |
| 2025Q2 | 2025-08-05 | 1.000 | 0.949 | 0.557 | 1,594 | 1,552 | 6 |
| 2025Q1 | 2025-05-01 | 1.020 | 0.894 | 0.333 | 1,513 | 1,508 | 5 |
| 2024Q4 | 2025-02-13 | 0.900 | 0.867 | 0.419 | 1,592 | 1,592 | 7 |
| 2024Q3 | 2024-10-31 | 0.870 | 0.903 | 1.382 | 1,582 | 1,564 | 7 |
| 2024Q2 | 2024-08-06 | 1.120 | 1.076 | 0.754 | 1,607 | 1,612 | 7 |
| 2024Q1 | 2024-05-02 | 1.220 | 0.978 | 0.778 | 1,622 | 1,565 | 7 |
| 2023Q4 | 2024-02-15 | 0.880 | 0.811 | 2.128 | 1,598 | 1,554 | 8 |
| 2023Q3 | 2023-11-02 | 0.870 | 1.050 | 0.226 | 1,519 | 1,574 | 8 |
| 2023Q2 | 2023-08-08 | 1.310 | 0.973 | 0.946 | 1,608 | 1,565 | 6 |
| 2023Q1 | 2023-05-04 | 1.080 | 1.166 | 0.691 | 1,538 | 1,542 | 7 |
| 2022Q4 | 2023-02-16 | 0.810 | 0.920 | 0.423 | 1,485 | 1,493 | 8 |
| 2022Q3 | 2022-11-03 | 1.320 | 1.101 | 0.890 | 1,537 | 1,514 | 7 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2020FY | 6.975 | - | 8.520 | 6,607 | - |
| 2021FY | 6.540 | 6.282 | 5.328 | 6,304 | 6,275 |
| 2022FY | 5.030 | 4.981 | 3.594 | 6,174 | 6,184 |
| 2023FY | 4.140 | 4.068 | 3.992 | 6,263 | 6,214 |
| 2024FY | 4.110 | 4.109 | 3.334 | 6,403 | 6,407 |
| 2025FY | 3.660 | 3.754 | 0.720 | 6,216 | 6,224 |
| 2026FY | - | 3.350 | - | - | 6,135 |
| 2027FY | - | 3.630 | - | - | 6,359 |
| 2028FY | - | 4.010 | - | - | 6,678 |
| 2029FY | - | 3.800 | - | - | 6,460 |
| 2030FY | - | 3.900 | - | - | 6,505 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | S | 2026-08-21 | 1 | 0 | 0 | 1,576 | 1,576 | 1,576 |
| 2026Q3 | S | 2026-08-11 | 1 | 0 | 0 | 1,569 | 1,569 | 1,569 |
| 2026Q3 | S | 2026-08-05 | 1 | 0 | 0 | 1,569 | 1,569 | 1,569 |
| 2026Q3 | S | 2026-08-02 | 2 | 0 | 0 | 1,581 | 1,569 | 1,593 |
| 2026Q3 | S | 2026-07-25 | 4 | 0 | 0 | 1,572 | 1,550 | 1,593 |
| 2026Q3 | S | 2026-06-02 | 5 | 0 | 0 | 1,568 | 1,550 | 1,593 |
| 2026Q3 | S | 2026-05-01 | 5 | 1 | 0 | 1,568 | 1,550 | 1,593 |
| 2026Q3 | S | 2026-04-30 | 5 | 1 | 0 | 1,570 | 1,550 | 1,593 |
| 2026Q3 | S | 2026-04-21 | 5 | 1 | 0 | 1,570 | 1,550 | 1,593 |
| 2026Q3 | S | 2026-04-20 | 4 | 0 | 0 | 1,575 | 1,555 | 1,593 |
| 2026Q3 | S | 2026-02-26 | 4 | 0 | 0 | 1,577 | 1,555 | 1,593 |
| 2026Q3 | S | 2026-02-18 | 4 | 0 | 0 | 1,580 | 1,565 | 1,593 |
| 2026Q3 | S | 2026-02-17 | 5 | 0 | 0 | 1,568 | 1,521 | 1,593 |
| 2026Q3 | S | 2026-02-13 | 4 | 0 | 0 | 1,565 | 1,521 | 1,593 |
Estimate history
| EPS, annual | 7.115 | 8.506 | 12.713 | 8.52 | 5.328 | 3.594 | 3.992 | 3.334 | 0.717 | 0.7688 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | 1.382 | 0.419 | 0.333 | 0.557 | 0.614 | -0.788 | 0.555 | 0.399 | 0.602 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Sales, annual | 10500 | 9777 | 9530 | 6535 | 6360 | 6174 | 6263 | 6403 | 6216 | 6099 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 1582 | 1592 | 1513 | 1594 | 1602 | 1507 | 1460 | 1558 | 1574 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Shares, annual | 253.13 | 253.13 | 253.13 | 253.516 | 253.55 | 254.37 | 255.626 | 257.799 | 260.316 | 262.622 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 257.539 | 257.799 | 257.95 | 259.965 | 259.983 | 260.316 | 262.649 | 262.609 | 262.622 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,099.00 | 6,216.00 | 6,403.00 | 6,263.00 | 6,174.00 | 6,360.00 | 6,535.00 | 9,530.00 | 9,777.00 |
| Cost of Goods Sold Incl. D&A | 2,834.00 | 2,854.00 | 2,688.00 | 2,515.00 | 2,280.00 | 2,382.00 | 2,119.00 | 3,614.00 | 4,686.00 |
| Gross Profit | 3,265.00 | 3,362.00 | 3,715.00 | 3,748.00 | 3,894.00 | 3,978.00 | 4,416.00 | 5,916.00 | 5,091.00 |
| Selling, General and Administrative Excl. Other | 2,069.00 | 2,087.00 | 2,217.00 | 2,421.00 | 2,175.00 | 2,106.00 | 1,566.00 | 2,254.00 | 2,378.00 |
| Research and Development | 357.00 | 366.00 | 469.00 | 528.00 | 471.00 | 443.00 | 210.00 | 332.00 | 365.00 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 1,196.00 | 1,275.00 | 1,498.00 | 1,327.00 | 1,719.00 | 1,872.00 | 2,850.00 | 3,662.00 | 2,713.00 |
| Interest Expense | 456.00 | 514.00 | 529.00 | 527.00 | 422.00 | 258.00 | 6.00 | 6.00 | 6.00 |
| Unusual Expense | 253.00 | 305.00 | 93.00 | 70.00 | 149.00 | 96.00 | 111.00 | 111.00 | 19.00 |
| Net Income Before Taxes | 503.00 | 425.00 | 807.00 | 673.00 | 1,122.00 | 1,529.00 | 2,752.00 | 3,555.00 | 2,729.00 |
| Income Taxes | 290.00 | 238.00 | -57.00 | -350.00 | 205.00 | 178.00 | 496.00 | 337.00 | 576.00 |
| Consolidated Net Income | 213.00 | 187.00 | 864.00 | 1,023.00 | 917.00 | 1,351.00 | 2,256.00 | 3,218.00 | 2,153.00 |
| Net Income From Continuing Operations | 213.00 | 187.00 | 864.00 | 1,023.00 | 917.00 | 1,351.00 | 2,256.00 | 3,218.00 | 2,153.00 |
| Net Income | 213.00 | 187.00 | 864.00 | 1,023.00 | 917.00 | 1,351.00 | 2,160.00 | 3,218.00 | 2,153.00 |
| EPS (Recurring) | 1.43 | 1.54 | 3.59 | 4.18 | 4.00 | 5.59 | 8.83 | 13.02 | 8.56 |
| EPS (Basic, Before Extraordinaries) | 0.81 | 0.72 | 3.36 | 4.01 | 3.61 | 5.33 | 8.52 | 12.71 | 8.51 |
| EPS (Diluted) | 0.77 | 0.72 | 3.33 | 3.99 | 3.59 | 5.33 | 8.52 | 12.71 | 8.51 |
| EBITDA | 1,533.00 | 1,636.00 | 1,775.00 | 1,563.00 | 1,931.00 | 2,067.00 | 2,992.00 | 4,016.00 | 4,386.00 |
| Non-Operating Income (Expense) | 16.00 | -31.00 | -69.00 | -57.00 | -26.00 | 11.00 | 13.00 | 10.00 | 41.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 56.53 | 61.00 | 83.00 | 80.00 | 59.00 | 47.00 | 32.00 | 41.00 | 44.00 |
| Price To Earnings Ratio | 18.07 | 18.07 | 2.96 | 6.31 | 7.04 | 5.71 | 5.13 | - | - |
| Price To Sales Ratio | 0.61 | 0.30 | 0.60 | 0.59 | 1.15 | 1.21 | - | - | - |
| Gross Margin | 53.53 | 54.09 | 58.02 | 59.84 | 63.07 | 62.55 | 67.57 | 62.08 | 52.07 |
| Operating Margin | 19.61 | 20.51 | 23.40 | 21.19 | 27.84 | 29.43 | 43.61 | 38.43 | 27.75 |
| Net Margin | 3.49 | 3.01 | 13.49 | 16.33 | 14.85 | 21.24 | 33.05 | 33.77 | 22.02 |
| Shares Outstanding | 262.62 | 260.32 | 257.80 | 255.63 | 254.37 | 253.55 | 253.52 | 253.13 | 253.13 |
| Market Capitalization | 3,647.82 | 3,647.82 | 3,842.48 | 3,685.84 | 7,104.39 | 7,720.60 | 7,791.59 | - | - |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,574.00 | 1,558.00 | 1,460.00 | 1,507.00 | 1,602.00 | 1,594.00 | 1,513.00 | 1,592.00 |
| Cost of Goods Sold Incl. D&A | 705.00 | 711.00 | 670.00 | 748.00 | 745.00 | 720.00 | 672.00 | 696.00 |
| Gross Profit | 869.00 | 847.00 | 790.00 | 759.00 | 857.00 | 874.00 | 841.00 | 896.00 |
| Selling, General and Administrative Excl. Other | 504.00 | 524.00 | 517.00 | 524.00 | 499.00 | 548.00 | 516.00 | 592.00 |
| Research and Development | 83.00 | 90.00 | 93.00 | 91.00 | 84.00 | 95.00 | 96.00 | 130.00 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 365.00 | 323.00 | 273.00 | 235.00 | 358.00 | 326.00 | 325.00 | 304.00 |
| Interest Expense | 109.00 | 111.00 | 113.00 | 123.00 | 131.00 | 132.00 | 128.00 | 136.00 |
| Unusual Expense | -15.00 | -18.00 | 31.00 | 255.00 | 4.00 | -4.00 | 97.00 | -15.00 |
| Net Income Before Taxes | 255.00 | 183.00 | 213.00 | -148.00 | 243.00 | 229.00 | 101.00 | 129.00 |
| Income Taxes | 91.00 | 75.00 | 67.00 | 57.00 | 83.00 | 84.00 | 14.00 | 20.00 |
| Consolidated Net Income | 164.00 | 108.00 | 146.00 | -205.00 | 160.00 | 145.00 | 87.00 | 109.00 |
| Net Income From Continuing Operations | 164.00 | 108.00 | 146.00 | -205.00 | 160.00 | 145.00 | 87.00 | 109.00 |
| Net Income | 164.00 | 108.00 | 146.00 | -205.00 | 160.00 | 145.00 | 87.00 | 109.00 |
| EPS (Recurring) | 0.56 | 0.35 | 0.64 | -0.10 | 0.62 | 0.55 | 0.59 | 0.38 |
| EPS (Basic, Before Extraordinaries) | 0.62 | 0.41 | 0.56 | -0.79 | 0.62 | 0.56 | 0.34 | 0.42 |
| EPS (Diluted) | 0.60 | 0.40 | 0.56 | -0.79 | 0.61 | 0.56 | 0.33 | 0.42 |
| EBITDA | 447.00 | 403.00 | 359.00 | 324.00 | 450.00 | 415.00 | 409.00 | 380.00 |
| Non-Operating Income (Expense) | -16.00 | -47.00 | 84.00 | -5.00 | 20.00 | 31.00 | 1.00 | -54.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 16.00 | 20.00 | 15.00 | 5.53 | 19.00 | 17.00 | 19.00 | 20.54 |
| Price To Earnings Ratio | 18.07 | 14.43 | 8.36 | 3.73 | 3.97 | 3.35 | 4.47 | 2.96 |
| Price To Sales Ratio | 0.61 | 0.60 | 0.26 | 0.30 | 0.44 | 0.40 | 0.62 | 0.61 |
| Gross Margin | 55.21 | 54.36 | 54.11 | 50.36 | 53.50 | 54.83 | 55.58 | 56.28 |
| Operating Margin | 23.19 | 20.73 | 18.70 | 15.59 | 22.35 | 20.45 | 21.48 | 19.10 |
| Net Margin | 10.42 | 6.93 | 10.00 | -13.60 | 9.99 | 9.10 | 5.75 | 6.85 |
| Shares Outstanding | 262.62 | 262.61 | 262.65 | 260.32 | 259.98 | 259.96 | 257.95 | 257.80 |
| Market Capitalization | 3,647.82 | 3,555.73 | 1,559.29 | 1,864.08 | 2,776.44 | 2,516.37 | 3,840.88 | 3,842.48 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 574.00 | 675.00 | 693.00 | 706.00 | 737.00 | 12.00 | 319.00 | 244.00 | - |
| Short Term Receivables | 1,433.00 | 1,491.00 | 1,857.00 | 1,606.00 | 1,512.00 | 1,405.00 | 1,573.00 | 1,605.00 | - |
| Inventories | 1,406.00 | 1,321.00 | 1,315.00 | 1,003.00 | 915.00 | 913.00 | 1,071.00 | 994.00 | - |
| Other Current Assets | 939.00 | 861.00 | 643.00 | 616.00 | 596.00 | 1,237.00 | 992.00 | 871.00 | - |
| Total Current Assets | 4,352.00 | 4,348.00 | 4,508.00 | 3,931.00 | 3,760.00 | 3,567.00 | 3,955.00 | 3,714.00 | - |
| Net Property, Plant & Equipment | 1,458.00 | 1,325.00 | 1,356.00 | 1,233.00 | 1,203.00 | 1,015.00 | 762.00 | 651.00 | - |
| Total Investments and Advances | 0.00 | 27.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Intangible Assets | 5,283.00 | 6,094.00 | 5,136.00 | 5,252.00 | 5,254.00 | 5,106.00 | 5,172.00 | 5,415.00 | - |
| Deferred Tax Assets | 985.00 | 946.00 | 808.00 | 267.00 | - | - | - | - | - |
| Other Assets | 789.00 | 361.00 | 250.00 | 272.00 | 464.00 | 421.00 | 659.00 | 714.00 | - |
| Total Assets | 12,867.00 | 13,101.00 | 12,058.00 | 10,955.00 | 10,681.00 | 10,109.00 | 10,548.00 | 10,494.00 | - |
| Short Term Debt Incl. Current Port. of LT Debt | 56.00 | 64.00 | 55.00 | 57.00 | 55.00 | 8.00 | 48.00 | 115.00 | - |
| Accounts Payable | 952.00 | 1,153.00 | 1,314.00 | 1,132.00 | 1,382.00 | 259.00 | 258.00 | 289.00 | - |
| Income Tax Payable | 85.00 | 134.00 | 206.00 | 184.00 | 185.00 | 288.00 | 242.00 | 322.00 | - |
| Other Current Liabilities | 1,297.00 | 1,367.00 | 1,343.00 | 1,139.00 | 975.00 | 2,118.00 | 793.00 | 819.00 | - |
| Total Current Liabilities | 2,390.00 | 2,718.00 | 2,918.00 | 2,512.00 | 2,597.00 | 2,673.00 | 1,341.00 | 1,545.00 | - |
| Long Term Debt | 8,744.00 | 8,972.00 | 8,876.00 | 9,055.00 | 9,309.00 | 23.00 | 138.00 | 34.00 | - |
| Provision for Risks Charges | 61.00 | 77.00 | 76.00 | 47.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Deferred Tax Liabilities | 57.00 | 74.00 | 47.00 | 19.00 | 4.00 | 128.00 | 139.00 | 149.00 | - |
| Other Liabilities | 863.00 | 788.00 | 211.00 | 214.00 | 279.00 | 1,799.00 | 1,895.00 | 2,418.00 | - |
| Total Liabilities | 12,115.00 | 12,629.00 | 12,128.00 | 11,847.00 | 12,189.00 | 4,623.00 | 3,513.00 | 4,146.00 | - |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Common Equity | 752.00 | 472.00 | -70.00 | -892.00 | -1,508.00 | 5,486.00 | 7,035.00 | 6,348.00 | - |
| Total Shareholders Equity | 752.00 | 472.00 | -70.00 | -892.00 | -1,508.00 | 5,486.00 | 7,035.00 | 6,348.00 | - |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Total Equity | 752.00 | 472.00 | -70.00 | -892.00 | -1,508.00 | 5,486.00 | 7,035.00 | 6,348.00 | - |
| Total Liabilities & Stockholders Equity | 12,867.00 | 13,101.00 | 12,058.00 | 10,955.00 | 10,681.00 | 10,109.00 | 10,548.00 | 10,494.00 | - |
| Book Value Per Share | 2.89 | 1.83 | -0.27 | -3.51 | -5.95 | 21.64 | 27.79 | 25.08 | - |
| Tangible Book Value Per Share | -17.41 | -21.81 | -20.37 | -24.15 | -26.67 | 1.50 | 7.36 | 3.69 | - |
| Full-Time Employees | 10,000 | 10,000 | 10,000 | 10,000 | 9,300 | 9,950 | 10,445 | - | - |
| Price to Book Ratio | 3.06 | 7.79 | -6.26 | -6.66 | -5.12 | -4.82 | - | - | - |
| Return on Assets | 1.44 | 6.87 | 8.89 | 8.48 | 13.12 | 21.84 | 30.59 | - | - |
| Return on Equity | 30.56 | 429.85 | - | - | 67.92 | 36.04 | 48.09 | - | - |
| Return on Invested Capital | 1.97 | 9.15 | 11.62 | 11.23 | 17.32 | 39.21 | 44.86 | 33.74 | - |
| Quick Ratio | 1.23 | 1.11 | 1.09 | 1.17 | 1.10 | 0.99 | 2.15 | 1.76 | - |
| Current Ratio | 1.82 | 1.60 | 1.54 | 1.56 | 1.45 | 1.33 | 2.95 | 2.40 | - |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 213.00 | 187.00 | 864.00 | 1,023.00 | 917.00 | 1,351.00 | 2,256.00 | 3,218.00 | 2,153.00 |
| Depreciation | 344.00 | 361.00 | 277.00 | 236.00 | 212.00 | 195.00 | 142.00 | 354.00 | 1,673.00 |
| Other Funds (Non Cash) | 239.00 | 336.00 | 236.00 | 180.00 | 199.00 | 498.00 | -62.00 | 41.00 | -2.00 |
| Funds from Operations | 858.00 | 947.00 | 1,217.00 | 954.00 | 1,310.00 | 1,756.00 | 2,304.00 | 3,679.00 | 3,861.00 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -15.00 | -247.00 | -278.00 | -155.00 | -452.00 | 702.00 | -117.00 | -912.00 | -174.00 |
| Income Taxes Payable | -32.00 | -61.00 | -65.00 | 16.00 | 7.00 | -119.00 | -118.00 | -590.00 | -166.00 |
| Cash from Operating Activities | 843.00 | 700.00 | 939.00 | 799.00 | 858.00 | 2,458.00 | 2,187.00 | 2,767.00 | 3,687.00 |
| Capital Expenditures | -108.00 | -192.00 | -246.00 | -259.00 | -303.00 | -296.00 | -255.00 | -109.00 | -101.00 |
| Net Assets From Acquisitions | -124.00 | -199.00 | -271.00 | -2.00 | -124.00 | -192.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 433.00 | 1.00 | 4.00 | 1.00 | 7.00 | 7.00 | 5.00 | 7.00 | 32.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 201.00 | -390.00 | -513.00 | -260.00 | -420.00 | -481.00 | -258.00 | -102.00 | -69.00 |
| Cash Dividends Paid | -20.00 | -88.00 | -297.00 | -294.00 | -290.00 | -145.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -214.00 | -458.00 | -49.00 | -258.00 | -108.00 | 7,728.00 | 1,512.00 | -44.00 | 59.00 |
| Change in Long Term Debt | -214.00 | -458.00 | -49.00 | -258.00 | -108.00 | 9,240.00 | 0.00 | -44.00 | 18.00 |
| Issuance of Long Term Debt | 325.00 | 1,055.00 | 1,148.00 | 80.00 | 0.00 | 9,352.00 | 0.00 | 0.00 | 18.00 |
| Reduction of Long Term Debt | -539.00 | -1,513.00 | -1,197.00 | -338.00 | -108.00 | -112.00 | 0.00 | -44.00 | 0.00 |
| Net Financing Active Other Cash Flow | -8.00 | -15.00 | -22.00 | -17.00 | -35.00 | -8,916.00 | -3,687.00 | -2,577.00 | -4,223.00 |
| Other Financing Activities Uses | -8.00 | -15.00 | -22.00 | -17.00 | -35.00 | -9,356.00 | -3,687.00 | -2,577.00 | -4,223.00 |
| Cash from Financing Activities | -242.00 | -561.00 | -368.00 | -569.00 | -433.00 | -1,333.00 | -2,175.00 | -2,621.00 | -4,164.00 |
| Exchange Rate Effect | -19.00 | 150.00 | -76.00 | 17.00 | -36.00 | 23.00 | -3.00 | 31.00 | 19.00 |
| Net Change in Cash | 783.00 | -101.00 | -18.00 | -13.00 | -31.00 | 667.00 | -249.00 | 75.00 | -527.00 |
| Free Cash Flow | 675.00 | 538.00 | 764.00 | 548.00 | 662.00 | 2,266.00 | 1,932.00 | 2,658.00 | 3,586.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 5.70 | 4.15 | 8.28 | 14.55 | 19.16 | 3.64 | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 63.00 | -160.00 | -485.00 | -18.00 | -288.00 | -32.00 | 66.00 | 37.00 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 1,455.00 | 1,132.00 | 1,116.00 | 574.00 | 672.00 | 599.00 |
| Short Term Receivables | 1,480.00 | 1,492.00 | 1,385.00 | 1,433.00 | 1,521.00 | 1,511.00 |
| Inventories | 1,355.00 | 1,351.00 | 1,373.00 | 1,406.00 | 1,488.00 | 1,454.00 |
| Other Current Assets | 1,079.00 | 1,136.00 | 1,058.00 | 939.00 | 1,019.00 | 1,054.00 |
| Total Current Assets | 5,369.00 | 5,111.00 | 4,932.00 | 4,352.00 | 4,700.00 | 4,618.00 |
| Net Property, Plant & Equipment | 1,286.00 | 1,281.00 | 1,279.00 | 1,458.00 | 1,290.00 | 1,266.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 5,218.00 | 5,265.00 | 5,252.00 | 5,283.00 | 6,020.00 | 6,042.00 |
| Deferred Tax Assets | - | - | - | 985.00 | - | - |
| Other Assets | 1,528.00 | 1,521.00 | 1,533.00 | 789.00 | 1,542.00 | 1,574.00 |
| Total Assets | 13,401.00 | 13,178.00 | 12,996.00 | 12,867.00 | 13,552.00 | 13,500.00 |
| Short Term Debt Incl. Current Port. of LT Debt | 69.00 | 74.00 | 16.00 | 56.00 | 45.00 | 115.00 |
| Accounts Payable | 982.00 | 1,051.00 | 983.00 | 952.00 | 1,074.00 | 1,067.00 |
| Income Tax Payable | 79.00 | 84.00 | 77.00 | 85.00 | 116.00 | 194.00 |
| Other Current Liabilities | 1,522.00 | 1,407.00 | 1,424.00 | 1,297.00 | 1,444.00 | 1,420.00 |
| Total Current Liabilities | 2,652.00 | 2,616.00 | 2,500.00 | 2,390.00 | 2,679.00 | 2,796.00 |
| Long Term Debt | 8,485.00 | 8,479.00 | 8,553.00 | 8,744.00 | 8,783.00 | 8,781.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 61.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 45.00 | 51.00 | 56.00 | 57.00 | 62.00 | 69.00 |
| Other Liabilities | 1,026.00 | 1,026.00 | 984.00 | 863.00 | 1,122.00 | 1,121.00 |
| Total Liabilities | 12,208.00 | 12,172.00 | 12,093.00 | 12,115.00 | 12,646.00 | 12,767.00 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 1,193.00 | 1,006.00 | 903.00 | 752.00 | 906.00 | 733.00 |
| Total Shareholders Equity | 1,193.00 | 1,006.00 | 903.00 | 752.00 | 906.00 | 733.00 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 1,193.00 | 1,006.00 | 903.00 | 752.00 | 906.00 | 733.00 |
| Total Liabilities & Stockholders Equity | 13,401.00 | 13,178.00 | 12,996.00 | 12,867.00 | 13,552.00 | 13,500.00 |
| Book Value Per Share | 4.54 | 3.83 | 3.44 | 2.89 | 3.48 | 2.82 |
| Tangible Book Value Per Share | -15.33 | -16.22 | -16.56 | -17.41 | -19.67 | -20.42 |
| Full-Time Employees | - | - | - | 10,000 | - | - |
| Price to Book Ratio | 3.06 | 3.94 | 2.07 | 2.06 | 3.79 | 4.61 |
| Return on Assets | 1.58 | 1.57 | 1.88 | 1.44 | 3.81 | 5.46 |
| Return on Equity | 20.30 | 24.04 | 34.05 | 30.56 | 71.62 | 159.64 |
| Return on Invested Capital | 1.69 | 1.14 | 1.54 | -2.16 | 1.65 | 1.52 |
| Quick Ratio | 1.51 | 1.44 | 1.42 | 1.23 | 1.20 | 1.13 |
| Current Ratio | 2.02 | 1.95 | 1.97 | 1.82 | 1.75 | 1.65 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | 164.00 | 108.00 | 146.00 | -205.00 | 160.00 | 145.00 |
| Depreciation | 82.00 | 80.00 | 86.00 | 96.00 | 92.00 | 89.00 |
| Other Funds (Non Cash) | 9.00 | 28.00 | -52.00 | 254.00 | -1.00 | 37.00 |
| Funds from Operations | 268.00 | 232.00 | 183.00 | 175.00 | 291.00 | 281.00 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 102.00 | -125.00 | 42.00 | -34.00 | -27.00 | -61.00 |
| Income Taxes Payable | -4.00 | 7.00 | -4.00 | -31.00 | -76.00 | 8.00 |
| Cash from Operating Activities | 370.00 | 107.00 | 225.00 | 141.00 | 264.00 | 220.00 |
| Capital Expenditures | -44.00 | -76.00 | -47.00 | 59.00 | -115.00 | -39.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | -124.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 433.00 | 0.00 | 0.00 | 1.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -44.00 | -76.00 | 386.00 | -65.00 | -115.00 | -38.00 |
| Cash Dividends Paid | -5.00 | -6.00 | -5.00 | -4.00 | -3.00 | -10.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | -32.00 | -182.00 | -72.00 | -201.00 |
| Change in Long Term Debt | 0.00 | 0.00 | -32.00 | -182.00 | -72.00 | -201.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 325.00 | 300.00 | 340.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | -32.00 | -507.00 | -372.00 | -541.00 |
| Net Financing Active Other Cash Flow | 0.00 | -6.00 | -1.00 | -1.00 | -1.00 | -12.00 |
| Other Financing Activities Uses | 0.00 | -6.00 | -1.00 | -1.00 | -1.00 | -12.00 |
| Cash from Financing Activities | -5.00 | -12.00 | -38.00 | -187.00 | -76.00 | -223.00 |
| Exchange Rate Effect | 2.00 | -3.00 | -31.00 | 13.00 | 0.00 | 93.00 |
| Net Change in Cash | 323.00 | 16.00 | 542.00 | -98.00 | 73.00 | 52.00 |
| Free Cash Flow | 326.00 | 65.00 | 188.00 | 96.00 | 218.00 | 181.00 |
| Price to Free Cash Flow | 5.70 | 6.67 | 2.38 | 4.15 | 4.50 | 5.87 |
Revenue breakdown
| Arcoxia | 2024: 270.00M 2025: 265.00M |
|---|---|
| Atozet | 2024: 473.00M 2025: 324.00M |
| Brenzys | 2024: 77.00M 2025: 80.00M |
| Clarinex | 2024: 127.00M 2025: 123.00M |
| Cozaar/Hyzaar | 2024: 243.00M 2025: 219.00M |
| Diprospan | 2024: 139.00M 2025: 150.00M |
| Dulera | 2024: 203.00M 2025: 153.00M |
| Emgality/Ravvow | 2024: 107.00M 2025: 174.00M |
| Follistim AQ | 2024: 237.00M 2025: 264.00M |
| Fosamax | 2024: 151.00M 2025: 143.00M |
| Ganirelix Acetate Injection | 2024: 109.00M 2025: 101.00M |
| Hadlima | 2024: 142.00M 2025: 228.00M |
| Jada | 2024: 61.00M 2025: 74.00M |
| Marvelon/Mercilon | 2024: 134.00M 2025: 127.00M |
| Nasonex | 2024: 276.00M 2025: 262.00M |
| Nexplanon/Implanon NXT | 2024: 963.00M 2025: 921.00M |
| NuvaRing | 2024: 115.00M 2025: 91.00M |
| Ontruzant | 2024: 141.00M 2025: 99.00M |
| Other Biosimilars | 2024: 28.00M 2025: 33.00M |
| Other Cardiovascular | 2024: 133.00M 2025: 126.00M |
| Other Non-Opiod Pain, Bone and Dermatology | 2024: 295.00M 2025: 301.00M |
| Other Respiratory | 2024: 53.00M 2025: 52.00M |
| Other Sundry Established Brands | 2024: 328.00M 2025: 338.00M |
| Other Sundry Products | 2024: 115.00M 2025: 82.00M |
| Other Womens Health | 2024: 158.00M 2025: 174.00M |
| Propecia | 2024: 111.00M 2025: 118.00M |
| Proscar | 2024: 95.00M 2025: 97.00M |
| Renflexis | 2024: 274.00M 2025: 251.00M |
| Rosuzet | 2024: 49.00M 2025: 24.00M |
| Singulair | 2024: 359.00M 2025: 252.00M |
| Vtama | 2024: 12.00M 2025: 128.00M |
| Vytorin | 2024: 108.00M 2025: 100.00M |
| Zetia | 2024: 317.00M 2025: 342.00M |
| Asia Pacific and Japan | 2024: 1.05B 2025: 1.00B |
| China | 2024: 847.00M 2025: 829.00M |
| Europe And Canada | 2024: 1.76B 2025: 1.62B |
| Latin America, Middle East, Russia And Africa | 2024: 1.03B 2025: 1.07B |
| Other Countries | 2024: 137.00M 2025: 93.00M |
| United States | 2024: 1.57B 2025: 1.60B |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 7.55% | 19.7M | 260.9M | 2.58M |
| 2026-10-15 | 7.21% | 18.8M | 260.9M | 2.65M |
| 2026-09-30 | 7.27% | 19.0M | 260.9M | 2.71M |
| 2026-09-15 | 6.72% | 17.5M | 260.9M | 2.78M |
| 2026-08-31 | 6.40% | 16.7M | 260.9M | 2.66M |
| 2026-08-14 | 5.80% | 15.1M | 260.9M | 2.65M |
| 2026-07-31 | 6.42% | 16.8M | 261.7M | 3.31M |
| 2026-07-15 | 6.21% | 16.2M | 261.6M | 7.28M |
| 2026-06-30 | 6.53% | 17.1M | 261.6M | 8.38M |
| 2026-06-15 | 7.28% | 19.0M | 261.3M | 8.50M |
| 2026-05-29 | 6.92% | 18.1M | 261.4M | 8.71M |
| 2026-05-15 | 7.67% | 20.0M | 261.3M | 8.86M |
| 2026-04-30 | 7.46% | 19.5M | 261.2M | 8.74M |
| 2026-04-15 | 7.19% | 18.6M | 259.0M | 5.54M |
| 2026-03-31 | 8.54% | 22.1M | 259.1M | 4.96M |
| 2026-03-13 | 7.46% | 19.3M | 259.1M | 5.10M |
| 2026-02-27 | 6.28% | 16.3M | 259.1M | 5.29M |
| 2026-02-13 | 6.77% | 17.5M | 259.1M | 5.46M |
| 2026-01-30 | 5.56% | 14.4M | 259.0M | 5.91M |
| 2026-01-15 | 6.00% | 15.5M | 259.0M | 6.31M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 6.00 | 5.80 | 10.00 | 0.00 | 9.585 | 0.00 | 0.00 | 0.981 | -0.016 | 0.001 |
| call | 7.00 | 4.80 | 9.00 | 0.00 | 8.190 | 0.00 | 0.00 | 0.977 | -0.016 | 0.001 |
| call | 8.00 | 3.80 | 8.00 | 0.00 | 7.047 | 0.00 | 0.00 | 0.973 | -0.016 | 0.001 |
| call | 9.00 | 2.85 | 7.00 | 0.00 | 6.075 | 0.00 | 0.00 | 0.967 | -0.015 | 0.002 |
| call | 10.00 | 1.85 | 6.00 | 0.00 | 5.221 | 0.00 | 0.00 | 0.959 | -0.014 | 0.002 |
| call | 11.00 | 0.85 | 4.90 | 0.00 | 4.295 | 0.00 | 0.00 | 0.947 | -0.014 | 0.002 |
| call | 12.00 | 1.40 | 4.10 | 0.00 | 3.872 | 0.00 | 0.00 | 0.926 | -0.012 | 0.003 |
| call | 13.00 | 0.00 | 1.10 | 0.97 | 0.657 | 3.00 | 0.00 | 0.847 | -0.013 | 0.005 |
| call | 14.00 | 0.00 | 0.05 | 0.03 | 0.099 | 45.00 | 0.00 | 0.524 | -0.055 | 0.009 |
| call | 15.00 | 0.00 | 0.05 | 0.05 | 0.407 | 24.00 | 0.00 | 0.238 | -0.024 | 0.007 |
| call | 16.00 | 0.00 | 0.15 | 0.00 | 0.599 | 0.00 | 0.00 | 0.083 | -0.011 | 0.003 |
| call | 17.00 | 0.00 | 0.95 | 0.00 | 0.822 | 0.00 | 0.00 | 0.067 | -0.013 | 0.003 |
| call | 18.00 | 0.00 | 2.15 | 0.00 | 0.995 | 0.00 | 0.00 | 0.057 | -0.014 | 0.003 |
| call | 19.00 | 0.00 | 2.15 | 0.00 | 1.152 | 0.00 | 0.00 | 0.051 | -0.014 | 0.002 |
| call | 20.00 | 0.00 | 2.15 | 0.00 | 1.296 | 0.00 | 0.00 | 0.046 | -0.015 | 0.002 |
| call | 21.00 | 0.00 | 0.05 | 0.00 | 1.372 | 0.00 | 0.00 | 0.043 | -0.014 | 0.002 |
| call | 22.00 | 0.00 | 2.15 | 0.00 | 1.556 | 0.00 | 0.00 | 0.040 | -0.016 | 0.002 |
| put | 6.00 | 0.00 | 0.05 | 0.00 | 2.883 | 0.00 | 0.00 | -0.019 | -0.016 | 0.001 |
| put | 7.00 | 0.00 | 0.05 | 0.00 | 2.404 | 0.00 | 0.00 | -0.022 | -0.016 | 0.001 |
| put | 8.00 | 0.00 | 0.05 | 0.00 | 1.987 | 0.00 | 0.00 | -0.027 | -0.015 | 0.001 |
| put | 9.00 | 0.00 | 0.05 | 0.00 | 1.616 | 0.00 | 0.00 | -0.033 | -0.014 | 0.002 |
| put | 10.00 | 0.00 | 0.05 | 0.00 | 1.278 | 0.00 | 0.00 | -0.041 | -0.014 | 0.002 |
| put | 11.00 | 0.00 | 0.10 | 0.00 | 0.965 | 0.00 | 0.00 | -0.053 | -0.013 | 0.002 |
| put | 12.00 | 0.00 | 2.15 | 0.00 | 0.659 | 0.00 | 0.00 | -0.074 | -0.011 | 0.003 |
| put | 13.00 | 0.00 | 0.05 | 0.05 | 0.359 | 2.00 | 0.00 | -0.147 | -0.011 | 0.005 |
| put | 14.00 | 0.00 | 2.25 | 0.16 | 2.532 | 2.00 | 0.00 | -0.480 | -0.058 | 0.009 |
| put | 15.00 | 0.20 | 3.30 | 0.00 | 3.023 | 0.00 | 0.00 | -0.762 | -0.023 | 0.007 |
| put | 16.00 | 1.60 | 4.30 | 2.07 | 3.398 | 1.00 | 0.00 | -0.917 | -0.010 | 0.003 |
| put | 17.00 | 2.10 | 5.30 | 3.05 | 3.720 | 1.00 | 0.00 | -0.933 | -0.011 | 0.003 |
| put | 18.00 | 3.80 | 6.30 | 4.03 | 4.000 | 0.00 | 0.00 | -0.943 | -0.012 | 0.002 |
| put | 19.00 | 4.80 | 7.30 | 5.07 | 4.259 | 0.00 | 0.00 | -0.949 | -0.013 | 0.002 |
| put | 20.00 | 5.80 | 8.30 | 6.19 | 4.494 | 0.00 | 0.00 | -0.954 | -0.013 | 0.002 |
| put | 21.00 | 6.10 | 9.30 | 7.18 | 4.717 | 1.00 | 0.00 | -0.957 | -0.014 | 0.002 |
| put | 22.00 | 6.10 | 10.30 | 0.00 | 4.911 | 0.00 | 0.00 | -0.960 | -0.014 | 0.002 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-07 | SEC |
| 2026-11-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-07 | SEC |
| 2026-11-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-10-30 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-10-30 | 8-K | Current report | 2026-10-30 | SEC |
| 2026-08-14 | SCHEDULE 13G | SEC | ||
| 2026-08-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-05 | SEC |
| 2026-07-31 | SCHEDULE 13G/A | SEC | ||
| 2026-07-31 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-31 | 8-K | Current report | 2026-07-31 | SEC |
| 2026-07-23 | 8-K | Current report | 2026-07-23 | SEC |
| 2026-07-17 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-07-17 | 8-K | Current report | 2026-07-17 | SEC |
| 2026-06-17 | DEFM14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-11 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-06-11 | 8-K | Current report | 2026-06-09 | SEC |
| 2026-06-01 | PREM14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-05-29 | SEC |
| 2026-05-29 | SD | Specialized Disclosure Report | SEC | |
| 2026-05-08 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-05-07 | 4/A | 2026-05-06 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 200.31K | 1 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 353.08K | 1 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 501.76K | 1 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 12.21% |
| Pentwater Capital Management LP | 6.89% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.76% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.54% |
| FIL Ltd | 4.00% |
| STATE STREET CORP | 3.68% |
| GOLDMAN SACHS GROUP INC | 1.98% |
| ALLIANCEBERNSTEIN L.P. | 1.81% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.77% |
| UBS Group AG | 1.69% |
Funds
| Fund | % owned |
|---|---|
| Lord Abbett Short Duration Income Fund | 48.65% |
| NYLIM MacKay High Yield Corporate Bond Fund | 20.35% |
| Lord Abbett Income Fund | 11.85% |
| NYLIM MacKay Short Duration High Income Fund | 9.98% |
| Lord Abbett Floating Rate Fund | 7.12% |
| JPMorgan High Yield Fund | 6.57% |
| iShares Core S&P Small-Cap ETF | 6.02% |
| American Funds Multi-Sector Income Fund | 5.71% |
| NYLIM VP MacKay High Yield Corporate Bond Portfolio | 4.89% |
| JPMorgan Income Fund | 4.74% |
OakChart. OGN. Cached 15 minutes.